<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="publisher-id">JCTH</journal-id><journal-title-group><journal-title>Journal of Clinical and Translational Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2225-0719</issn><issn pub-type="epub">2310-8819</issn><publisher><publisher-name>XIA &#x00026; HE Publishing Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9396319</article-id><article-id pub-id-type="publisher-id">JCTH.2021.00368</article-id><article-id pub-id-type="doi">10.14218/JCTH.2021.00368</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment</article-title><alt-title alt-title-type="running-head-verso">Zhang R. <italic>et al</italic>: Liver function in COVID-19 patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Rongzhi</given-names></name><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1273-7021</contrib-id></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qiang</given-names></name><xref rid="aff2" ref-type="aff">2</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9855-6730</contrib-id></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jianshe</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>1</label>The Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China</aff><aff id="aff2"><label>2</label>Gansu Medical College, Pingliang, Gansu, China</aff><aff id="aff3"><label>3</label>Shanghai Tenth People&#x02019;s Hospital, Tongji University School of Medicine, Shanghai, China</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label><bold>Correspondence to:</bold> Jianshe Yang, Shanghai Tenth People&#x02019;s Hospital, Tongji University School of Medicine, Shanghai 200072, China. ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7069-6072" ext-link-type="uri">https://orcid.org/0000-0001-7069-6072</ext-link>. Tel/Fax: +86-21-66302721, E-mail: <email>yangjs@impcas.ac.cn</email></corresp><fn fn-type="financial-disclosure"><p>This work was supported by the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (Grant No. CY2019-BJ07) and the Gansu Natural Science Foundation (Grant No. 20JR10RA745).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflict of interests related to this publication.</p></fn><fn fn-type="con"><p>Design of the work (JY) and writing of the manuscript (RZ, QW, JY). All authors have read and approved the final manuscript.</p></fn></author-notes><pub-date pub-type="ppub"><day>28</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>4</day><month>1</month><year>2022</year></pub-date><volume>10</volume><issue>4</issue><fpage>748</fpage><lpage>756</lpage><history><date date-type="received"><day>26</day><month>8</month><year>2021</year></date><date date-type="rev-recd"><day>17</day><month>9</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Liver injury is an important complication that may arise in patients suffering from coronavirus disease 2019 (COVID-19) and is accompanied by a transient increase of transaminases and/or other liver enzymes. Liver function test (LFT) abnormalities generally disappear when the COVID-19 resolves or hepatotoxic drugs are discontinued. The LFT abnormalities are associated with drug-induced liver injury (DILI), due to the overuse of antimalarials, antivirals, and antimicrobials. Studies have reported varying levels of these liver injuries in COVID-19 patients; however, most involve elevated serum aminotransferases. Hepatic dysfunction is significantly high in patients with severe illness and has poor outcome. Normally, the liver is involved in the metabolism of many drugs, including nucleoside analogs and protease inhibitors, which are currently repurposed to treat COVID-19. In addition to the manifestation of COVID-19, drugs implemented in its treatment may aggravate liver injuries. Thus, DILI should be considered especially in those COVID-19 patients with underlying liver disease. It was unclear whether the elevated liver enzymes have originated from the underlying disease or DILI in this population. Furthermore, it is difficult to establish a direct relationship between a specific drug and liver injury. Another possible effect of liver damage may due to inflammatory cytokine storm in severe COVID-19. Liver injury can change metabolism, excretion, dosing, and expected concentrations of the drugs, which may make it difficult to achieve a therapeutic dose of the drug or increase the risk of adverse effects. These repurposed drugs have shown limited efficacy against the virus and the disease itself; however, they still pose risk of adverse effects. Careful and close monitoring of LFTs in COVID-19 patients can provide early diagnosis of liver injury, and the risk of DILI could be reduced. Also, drug interactions in liver-transplanted patients should always be kept in mind for certain immunosuppressive therapies and their known signs of DILI. Altogether, abnormal LFTs should not be regarded as a contraindication to use COVID-19 experimental therapies if needed under emergent status.</p></abstract><abstract abstract-type="graphical"><title>Graphical abstract</title><p>
<graphic xlink:href="JCTH-10-748-ga.jpg" position="anchor"/>
</p></abstract><kwd-group><kwd>Liver injury</kwd><kwd>Hepatotoxicity</kwd><kwd>COVID-19</kwd><kwd>Antivirals</kwd><kwd>Aminotransferases</kwd><kwd>DILI</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Coronavirus disease 2019 (COVID-19) continues to affect our lives, yet there are still no specific antiviral therapies for it. Global efforts have been put forth to develop a vaccine against the causative pathogen, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), due to the knowledge that vaccines are the most efficient method against viruses. The routine strategy for creating such a vaccine includes exploration of mRNA, inactivated viruses, DNA and/or recombinant protein, and viral vectors. However, the time consumption requirement of around 18 months or more makes it even harder to develop an efficacious vaccine in a timely manner, although massive-scale efforts are underway. In the meantime, a number of drugs used for other diseases have been repurposed to tackle the COVID-19 pandemic, since this approach may be one of the quickest ways to discover an efficacious treatment for this new viral infection.</p><p>Since the SARS-CoV-2 shares extensive homology with SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), effective therapies for these two viruses may also have therapeutic potential for the current SARS-CoV-2 outbreak.</p><p>Besides mainly targeting the respiratory system, SARS-CoV-2 attacks nearly all the other organs and systems, causing myocardial damage, acute coronary syndromes, acute kidney injury, gastrointestinal symptoms, and liver injury.<xref rid="JCTH-D-21-00368-b1" ref-type="bibr">1</xref> Liver injury is an important complication observed in COVID-19 patients. A ephemeral increase of transaminases and/or other liver enzymes may occur in COVID-19 patients within the range of 10.5&#x02013;53.1%.<xref rid="JCTH-D-21-00368-b2" ref-type="bibr">2</xref>,<xref rid="JCTH-D-21-00368-b3" ref-type="bibr">3</xref> These abnormalities are generally self-limiting, mild to moderate increases, and mainly seen among symptomatic and severe COVID-19 patients.<xref rid="JCTH-D-21-00368-b3" ref-type="bibr">3</xref>,<xref rid="JCTH-D-21-00368-b4" ref-type="bibr">4</xref> Liver function test (LFT) abnormalities generally disappear when the COVID-19 infection resolves or hepatotoxic drugs are discontinued.<xref rid="JCTH-D-21-00368-b5" ref-type="bibr">5</xref></p><p>Although the underlying mechanisms remain unknown, virus-induced inflammation, liver hypoxia and drug-induced liver injury (DILI) are three primary factors associated with hepatic injury.<xref rid="JCTH-D-21-00368-b6" ref-type="bibr">6</xref> LFT abnormalities associated with DILI due to the overuse of antimalarials, antivirals, and antimicrobials during COVID-19 necessitate special attention of the attending physicians.<xref rid="JCTH-D-21-00368-b7" ref-type="bibr">7</xref></p><p>Rising levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) are frequently indicative of hepatocellular damage, while this trend for alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) is associated with bile duct damage or cholestasis. Serum bilirubin levels indicate liver secretion capacity, while serum albumin level and prothrombin time indicate liver synthesis capacity. ALT and AST enzymes have wide tissue distributions. The AST enzyme is found in the liver, heart, kidney, brain, pancreas, and leucocytes; thus, isolated AST elevations usually indicate organ injury. ALT is also found in skeletal muscle, myocardium, lungs, and kidneys. Hence, minor AST and ALT elevations remain nonspecific, especially in severe illness with multiorgan injury, as in severe COVID-19. As expected, there is heterogeneity in the reported literature regarding the incidence and impact of liver injury in COVID-19.</p><p>We used &#x0201c;Boolean Operators&#x0201d; such as AND, OR and NOT to search relevant research articles/reviews from the PubMed for repurposed drugs applied as COVID-19 treatment. The repurposed drugs of chloroquine and hydroxychloroquine, remdesivir, ribavirin, umifenovir, and favipiravir are already being used in clinical trials to treat the COVID-19 patients. These drugs have been approved for a different indication and belong to diverse categories, such as antimalarial/antiparasitic, antiretroviral/anti-viral, or protective against rheumatoid arthritis. As described above, though a vaccine would be an ideal option for providing active immunity against the SARS-CoV-2, it is time-consuming. The repurposed drugs are the most viable option against SARS-CoV-2 currently. Hence, we searched, obtained and filtered the relevant articles in the literature, with the schema as shown in <xref rid="JCTH-D-21-00368-f1" ref-type="fig">Figure 1</xref>.</p><fig position="float" id="JCTH-D-21-00368-f1"><label>Fig. 1</label><caption><title>Schema of literature fetching and filtering for repurposed drugs in treatment to COVID-19 with DILI. DILI, drug-induced liver injury.</title></caption><graphic xlink:href="JCTH-10-748-g001" position="float"/></fig><p>We have searched the literature and screened published research articles to further investigation to determine which molecule the repurposed drug targets and their route of administration. Based on the literature survey, we divided the repurposed drugs that can be used for the trials to treat COVID-19 into four categories: (I) antimalarial/antiparasitic drugs; (II) drugs used for rheumatoid arthritis; (III) antiretroviral/antiviral drugs; (IV) others. Liver injuries were involved in each of these five categories. Altogether, a total of 106 articles/reviews (all in English language) containing &#x0201c;COVID-19 &#x00026; drug-induced liver injury&#x0201d; were screened and selected for analysis, among which there were 44 reviews, 5 books and documents, 1 meta-analysis and 1 systematic review, and 55 other type articles, including clinical trials.</p></sec><sec id="s2"><title>Liver and COVID-19</title><p>Studies have reported varying levels of liver injury in COVID-19 patients but mostly elevated serum aminotransferases.<xref rid="JCTH-D-21-00368-b8" ref-type="bibr">8</xref> Two to eleven percent of patients have existing chronic liver disease and 14&#x02013;53% develop hepatic dysfunction, particularly in severe COVID-19. Hepatic dysfunction is significantly high in severe patients and associated with poor outcomes.<xref rid="JCTH-D-21-00368-b3" ref-type="bibr">3</xref></p><p>In a study by Zhang <italic>et al</italic>.,<xref rid="JCTH-D-21-00368-b9" ref-type="bibr">9</xref> the mean level of ALT (37.9 vs. 21.2 IU/L), AST (38.9 vs. 24.4 IU/L), GGT (56.9 vs. 28.5 IU/L), and total bilirubin (14.1 vs. 10.3 mg/dL) was higher in severe COVID-19 patients than that in mild COVID-19 patients. Most of the LFTs in COVID-19 patients were found to be correlated with C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) levels. Histological examination of the needle biopsy specimens reveals mild sinusoidal dilatation and minimal lymphocytic infiltration, while other specific damages are absent. In another study with 417 COVID-19 patients, 21.8% developed severe disease, 318 had abnormal LFTs and 90 had signs of liver injury during hospitalization.<xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref></p><p>Goel <italic>et al</italic>.<xref rid="JCTH-D-21-00368-b7" ref-type="bibr">7</xref> showed that baseline and &#x02265;3&#x000d7;upper limit of normal (ULN) transaminase elevations was present in 61.2% and 9.4% of patients at admission, respectively. Furthermore, 72.1% and 22.4% of patients developed in baseline and &#x02265;3&#x000d7;ULN elevated transaminases during the course of COVID-19, respectively. However, bilirubin and ALP elevations were less likely to be apparent at admission (11.4% and 12.6%, respectively) and through the course of the disease (17.7% and 22%). All LFT changes were correlated with inflammatory markers, while hyperbilirubinemia was correlated with elevated mortality. On the other hand, the effect of AST and ALT levels on mortality are different, with elevated AST being associated with mortality but ALT with survival.</p><p>A study reported that the hospitalized patients have a 76.3% abnormal LFTs and 21.5% have liver injury. Patients with severe pneumonia tended to have abnormal LFTs. The emergence of abnormal LFTs (3&#x000d7;ULN) was more common in the first 2 weeks of hospitalization. Lopinavir/ritonavir (LPV/r) treatment was found to be related to increased risk for liver injury.<xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref> In another study, it was reported that liver injury occurred in 14.8% of COVID-19 patients, mostly in severe cases. They also stated that liver injury occurred after administrating multiple drugs, such as LPV/r (18.6%), which are tightly associated with liver morbidity.<xref rid="JCTH-D-21-00368-b11" ref-type="bibr">11</xref> Huang <italic>et al</italic>.,<xref rid="JCTH-D-21-00368-b12" ref-type="bibr">12</xref> have reported that 30.7% of COVID-19 patients were diagnosed with nonalcoholic fatty liver disease (NAFLD) and 35.7% had abnormal LFTs, according to the clinical features of COVID-19 patients with NAFLD. The median ALT levels (35 IU/L vs. 23 U/L) and the elevated ALT (&#x0003e;40 U/L) (40.7% vs. 10.8%) were significantly higher in patients with NAFLD compared to those without, respectively. Multivariate analysis showed that age &#x0003e;50 years and concurrent NAFLD were independent risk factors of ALT elevation; however, the usage of interferon &#x003b1;-2b inhalation reduced the risk of ALT elevation.</p></sec><sec id="s3"><title>Liver and Proposed Drugs of COVID-19</title><sec id="s3a"><title>Effects of drugs on liver function</title><p>The liver is a principal site for the metabolization and elimination of chemical substances. Besides, it is involved in the metabolism of various drugs, including nucleoside analogs and protease inhibitors, which are currently repurposed for COVID-19 treatment. In addition to the manifestation of COVID-19, drugs implemented in its treatment may aggravate liver injury. Thus, DILI should be further evaluated especially for those patients with underlying liver disease.<xref rid="JCTH-D-21-00368-b13" ref-type="bibr">13</xref> It has remained unclear where the elevated liver enzymes originate from (either the disease or DILI) in this population. It has also been difficult to confirm the direct relationship between a specific drug and liver injury, due to the common combined use of antimalarials, antivirals, antimicrobials, and anticoagulants during COVID-19.<xref rid="JCTH-D-21-00368-b14" ref-type="bibr">14</xref> Finally, inflammatory cytokine storms in severe COVID-19 can result in liver damage.<xref rid="JCTH-D-21-00368-b13" ref-type="bibr">13</xref></p><p>Some medications previously used to treat a variety of other diseases, i.e. antivirals (such as LPV/r, remdesivir, ribavirin, favipiravir, umifenovir), antimalarials (chloroquine and hydroxychloroquine), antimicrobials (azithromycin, interferons), and immunomodulators (corticosteroids, tocilizumab) have been the widely repurposed in the fight against COVID-19.<xref rid="JCTH-D-21-00368-b15" ref-type="bibr">15</xref> These drugs have a comparable risk for liver injury (<xref rid="JCTH-D-21-00368-t1" ref-type="table">Table 1</xref>).<xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref>,<xref rid="JCTH-D-21-00368-b11" ref-type="bibr">11</xref>,<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref>&#x02013;<xref rid="JCTH-D-21-00368-b37" ref-type="bibr">37</xref></p><table-wrap position="float" id="JCTH-D-21-00368-t1"><label>Table 1</label><caption><title>Changes in liver functions and liver enzymes in COVID-19 trials</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Drugs</th><th align="left" rowspan="1" colspan="1">Toxicity</th><th colspan="2" align="left" rowspan="1">Type of toxicity</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">LPV/r</td><td align="left" valign="top" rowspan="1" colspan="1">8.8%</td><td colspan="2" align="left" valign="top" rowspan="1">ALT elevation (&#x0003e;3 ULN)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">4.8%</td><td colspan="2" align="left" valign="top" rowspan="1">AST elevation (&#x0003e;3 ULN)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">10.3%</td><td colspan="2" align="left" valign="top" rowspan="1">GGT elevation (&#x0003e;3 ULN)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">2.6%</td><td colspan="2" align="left" valign="top" rowspan="1">Total bilirubin elevation (&#x0003e;3 ULN)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">18.6%</td><td colspan="2" align="left" valign="top" rowspan="1">Liver injury</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b11" ref-type="bibr">11</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">37.2%</td><td colspan="2" align="left" valign="top" rowspan="1">Liver injury</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b17" ref-type="bibr">17</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">63.8%</td><td colspan="2" align="left" valign="top" rowspan="1">Any adverse drug effect</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">57.8%</td><td colspan="2" align="left" valign="top" rowspan="1">Elevation is more than the ULN value (ALT, AST, ALP, GGT, and total bilirubin)</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b19" ref-type="bibr">19</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Umifenovir</td><td align="left" valign="top" rowspan="1" colspan="1">18.1%</td><td colspan="2" align="left" valign="top" rowspan="1">Any adverse drug effect</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remdesivir</td><td align="left" valign="top" rowspan="1" colspan="1">15.2%</td><td colspan="2" align="left" valign="top" rowspan="1">Liver injury</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b17" ref-type="bibr">17</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">3.4%</td><td colspan="2" align="left" valign="top" rowspan="1">AST elevation</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b21" ref-type="bibr">21</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">2.3%</td><td colspan="2" align="left" valign="top" rowspan="1">ALT elevation</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7%</td><td colspan="2" align="left" valign="top" rowspan="1">ALT elevation</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b22" ref-type="bibr">22</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">5.8%</td><td colspan="2" align="left" valign="top" rowspan="1">AST elevation</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">32%</td><td colspan="2" align="left" valign="top" rowspan="1">AST-ALT elevation</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b23" ref-type="bibr">23</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">23%</td><td colspan="2" align="left" valign="top" rowspan="1">Increased LFTs</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b24" ref-type="bibr">24</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td colspan="2" align="left" valign="top" rowspan="1">Hyperbilirubinemia</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b25" ref-type="bibr">25</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">5%</td><td colspan="2" align="left" valign="top" rowspan="1">AST elevation</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">2%</td><td colspan="2" align="left" valign="top" rowspan="1">ALT elevation leading to discontinuation of remdesivir</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin Favipiravir</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td><td colspan="2" align="left" valign="top" rowspan="1">Elevation in serum aminotransferases</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">2.1-fold</td><td align="left" valign="top" rowspan="1" colspan="1">ALT and AST elevation</td><td align="left" valign="top" rowspan="1" colspan="1">CPT A</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b26" ref-type="bibr">26</xref>&#x02013;<xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">2.0-fold</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CPT B</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">3.7-fold</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">CPT C</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hydroxychloroquine</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold</td><td colspan="2" align="left" valign="top" rowspan="1">Elevation in transaminases</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b20" ref-type="bibr">20</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Azithromycin</td><td align="left" valign="top" rowspan="1" colspan="1">1&#x02013;2%</td><td colspan="2" align="left" valign="top" rowspan="1">Elevation in serum aminotransferases</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interferons</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td colspan="2" align="left" valign="top" rowspan="1">ALT and AST elevation, and mildly elevated ALP</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b19" ref-type="bibr">19</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corticosteroids</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td colspan="2" align="left" valign="top" rowspan="1">No ADEs for short duration</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b32" ref-type="bibr">32</xref>,<xref rid="JCTH-D-21-00368-b33" ref-type="bibr">33</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Convalescent plasma (antibody)</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td colspan="2" align="left" valign="top" rowspan="1">No detailed information</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref>,<xref rid="JCTH-D-21-00368-b34" ref-type="bibr">34</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tocilizumab</td><td align="left" valign="top" rowspan="1" colspan="1">Mild</td><td colspan="2" align="left" valign="top" rowspan="1">Liver enzyme elevation</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b29" ref-type="bibr">29</xref>&#x02013;<xref rid="JCTH-D-21-00368-b31" ref-type="bibr">31</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acetaminophen</td><td align="left" valign="top" rowspan="1" colspan="1">48%<sub>max</sub></td><td colspan="2" align="left" valign="top" rowspan="1">Dose-related hepatotoxicity</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b35" ref-type="bibr">35</xref>&#x02013;<xref rid="JCTH-D-21-00368-b37" ref-type="bibr">37</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>COVID-19, coronavirus disease 2019; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, gamma-glutamyl transferase; LFT, liver function test; LPV/r, lopinavir/ritonavir; ULN, upper limit of normal; CPT, Child Pugh Turcotte; ADEs, adverse drug events.</p></fn></table-wrap-foot></table-wrap><p>Cai <italic>et al</italic>.<xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref> demonstrated that patients under LPV/r had higher total bilirubin and GGT levels during hospitalization. In a study by Sun <italic>et al</italic>.,<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref> evaluating adverse drug events (ADEs) in 217 COVID-19 patients, ADEs were associated with LPV/r and umifenovir, at rates of 63.8% and 18.1%, respectively; in addition, liver system disorders were the most frequently observed ADEs, after gastrointestinal disorders. In a meta-analysis,<xref rid="JCTH-D-21-00368-b17" ref-type="bibr">17</xref> the pooled incidence of DILI among COVID-19 patients was 25.4%; DILI occurred in 37.2% and 15.2% of COVID19 patients receiving LPV/r and remdesivir, respectively.</p><p>Interferon-&#x003b2; is produced by recombinant technology and is a cytokine with antiviral, immunomodulatory and antiproliferative properties. Interferon-&#x003b2; is available in three subtypes &#x02013; 1a, 1b and pegylated &#x003b2;-1a &#x02013; and all are approved for use in multiple sclerosis by either subcutaneous or intramuscular administration.<xref rid="JCTH-D-21-00368-b38" ref-type="bibr">38</xref> All forms of interferon-&#x003b2; may also induce liver injury, though most of such cases are mild and even asymptomatic. Interferon-related DILI is transient, with mild elevations in serum aminotransferases (ALT and AST), and with normal or mildly elevated ALP levels.<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref> Whereas, LPV/r treatment had a higher rate of enzymes elevation (56% vs. 25%).<xref rid="JCTH-D-21-00368-b19" ref-type="bibr">19</xref></p><p>LPV/r administration will induce moderate to severe elevations in serum aminotransferase levels (&#x0003e;5&#x000d7;ULN). Low-dose ritonavir has less impact on the frequency or severity of LFT elevations. Additionally, ritonavir has some properties similar to an enzymatic inhibitor and it can increase the serum level of co-administered drugs, resulting in a higher risk of hepatotoxicity.<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref></p><p>Hydroxychloroquine and chloroquine are antiviral/immune modulators that are used for the treatment and prophylaxis of malaria, rheumatoid arthritis, lupus erythematosus, photodermatosis, and liver amoebiasis. Hydroxychloroquine is metabolized by several CYP enzymes in the liver, with desethylhydroxychloroquine being an active metabolite. The USA&#x02019;s Food and Drug Administration&#x02019;s prescribing information cautions use in patients with existing liver disease and/or concomitant use with hepatotoxic drugs.<xref rid="JCTH-D-21-00368-b39" ref-type="bibr">39</xref>,<xref rid="JCTH-D-21-00368-b40" ref-type="bibr">40</xref> Hydroxychloroquine is known to accumulate in the liver.<xref rid="JCTH-D-21-00368-b41" ref-type="bibr">41</xref> and animal studies have shown that accumulation occurs rapidly, in the first 2 weeks of treatment.<xref rid="JCTH-D-21-00368-b42" ref-type="bibr">42</xref> However, hydroxychloroquine was found to have a low hepatic extraction ratio, indicating that a reduction in liver blood flow in cirrhosis may not directly result in increased exposure to the drug.<xref rid="JCTH-D-21-00368-b43" ref-type="bibr">43</xref> Hydroxychloroquine is also known to be hydrophilic,<xref rid="JCTH-D-21-00368-b44" ref-type="bibr">44</xref> and this should be a consideration in patients with ascites and decompensated cirrhosis. Based on these lines of evidence, hydroxychloroquine is regarded as a possible but rare cause of DILI.<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref> Falcao <italic>et al</italic>.<xref rid="JCTH-D-21-00368-b20" ref-type="bibr">20</xref> reported a severe COVID-19 patient who showed a 10-fold increase of transaminases after using hydroxychloroquine, which returned to normal levels after withdrawal of the drug.</p><p>Remdesivir is a nucleotide analog for treatment of hepatitis C virus, used formerly.<xref rid="JCTH-D-21-00368-b45" ref-type="bibr">45</xref>,<xref rid="JCTH-D-21-00368-b46" ref-type="bibr">46</xref> Currently, data regarding hepatotoxicity of remdesivir is inadequate to draw firm conclusions. There was no liver injury in LiverTox,<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref> and liver toxicity data were not reported in Ebola trials; however, abnormal liver enzyme profiles are common during Ebola infection, making it difficult to rule-out accompanying drug-induced liver toxicity.<xref rid="JCTH-D-21-00368-b47" ref-type="bibr">47</xref>&#x02013;<xref rid="JCTH-D-21-00368-b49" ref-type="bibr">49</xref> The specificity of the cyano group in the remdesivir molecule allows for it to avoid inhibition by the host mitochondrial DNA polymerase and consequently limits the potential risk for lactic acidosis or mitochondrial toxicity. LFT elevations have varied widely among trials of remdesivir, accounting for 1% to 32% of participants.<xref rid="JCTH-D-21-00368-b21" ref-type="bibr">21</xref>&#x02013;<xref rid="JCTH-D-21-00368-b23" ref-type="bibr">23</xref> LFT elevation rate was 23% among 53 patients, which led to remdesivir discontinuation in two patients, while bilirubin elevation was not detected in that trial.<xref rid="JCTH-D-21-00368-b24" ref-type="bibr">24</xref> Wang <italic>et al</italic>.<xref rid="JCTH-D-21-00368-b25" ref-type="bibr">25</xref> showed that hypoalbuminemia, hyperbilirubinemia, and AST elevation were present in 13%, 10%, and 5% of patients treated with remdesivir, respectively; also, in the remdesivir group, three patients discontinued treatment due to ALT elevation. Sabers <italic>et al</italic>.<xref rid="JCTH-D-21-00368-b50" ref-type="bibr">50</xref> reported that a patient presented with high liver enzymes (&#x02265;20&#x000d7;ULN) and had received remdesivir; eventually, the patient&#x02019;s liver enzymes improved through the course of the disease and they were discharged on day 10 of hospitalization.</p><p>There is a theoretical risk of P-glycoprotein interaction with remdesivir. Inhibition of P-glycoprotein with comedications reduces efflux of remdesivir from hepatocytes, raising cellular remdesivir concentration to supratherapeutic levels. However, the occurrence of this interaction is very low, because of remdesivir being the minor substrate of P-glycoprotein, as well as its short half-life.<xref rid="JCTH-D-21-00368-b51" ref-type="bibr">51</xref> In the recent case report by Carothers <italic>et al</italic>.,<xref rid="JCTH-D-21-00368-b52" ref-type="bibr">52</xref> the benefit of acetylcysteine continuous infusion was investigated in acute liver injury related to remdesivir. Both of the two patients investigated showed significant increases in transaminase levels with coagulopathy and encephalopathy in response to remdesivir therapy; the continuous infusion of acetylcysteine rapidly resolved the high transaminase levels in these patients.</p><p>Favipiravir is a type of RNA-dependent RNA polymerase (RdRp) inhibitor. It presumably acts as a nucleotide analog that selectively inhibits the viral RdRp or causes lethal mutagenesis upon embedding into the virus RNA.<xref rid="JCTH-D-21-00368-b53" ref-type="bibr">53</xref>&#x02013;<xref rid="JCTH-D-21-00368-b57" ref-type="bibr">57</xref> Favipiravir, when used for the treatment of influenza, is administered at a dose of 1600 mg twice daily on day 1, followed by 600 mg twice daily on days 2&#x02013;5. Besides being a treatment for influenza virus,<xref rid="JCTH-D-21-00368-b58" ref-type="bibr">58</xref> favipiravir has shown potent antiviral activity against other segmented negative-strand RNA viruses in both <italic>in vitro</italic> and <italic>in vivo</italic> studies.<xref rid="JCTH-D-21-00368-b59" ref-type="bibr">59</xref>,<xref rid="JCTH-D-21-00368-b60" ref-type="bibr">60</xref> Furthermore, some positive-strand RNA viruses can also be inactivated by favipiravir,<xref rid="JCTH-D-21-00368-b61" ref-type="bibr">61</xref>,<xref rid="JCTH-D-21-00368-b62" ref-type="bibr">62</xref> and the virus replication process can be interfered with by the drug&#x02019;s competition with purine nucleosides, as has been shown to consequently inhibit the viral RdRp of SARS-CoV-2.<xref rid="JCTH-D-21-00368-b26" ref-type="bibr">26</xref> Studies have also shown that favipiravir administration provides better prognosis in COVID-19 patients in terms of disease progression and viral clearance.<xref rid="JCTH-D-21-00368-b27" ref-type="bibr">27</xref> ALT and AST elevation is just a possible adverse effect of favipiravir, however no data are available in cirrhosis patients.<xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref></p><p>Tocilizumab is a monoclonal antibody against the interleukin-6 (IL-6) receptor, which is usually used to treat the cytokine storm that occurs in the advanced stages of the disease.<xref rid="JCTH-D-21-00368-b63" ref-type="bibr">63</xref> Though small series and case reports suggest its beneficial effects, it was not proven in randomized controlled trials.<xref rid="JCTH-D-21-00368-b29" ref-type="bibr">29</xref>,<xref rid="JCTH-D-21-00368-b64" ref-type="bibr">64</xref>,<xref rid="JCTH-D-21-00368-b65" ref-type="bibr">65</xref> Tocilizumab administration can lead to liver enzyme elevation but rarely to severe liver injury.<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref> Recently, a patient with COVID-19 was reported on due to their transaminase levels increasing 40-fold after 24 h of initiation of tocilizumab administration.<xref rid="JCTH-D-21-00368-b66" ref-type="bibr">66</xref> Tocilizumab may pose a risk of hepatitis B virus (HBV) reactivation, thereby causing risk of indirect liver damage.<xref rid="JCTH-D-21-00368-b67" ref-type="bibr">67</xref> A study predicted that patients with severe COVID-19 and resolved HBV under immune modulator treatment had a low risk for HBV reactivation, and recommended that patients without antibodies to hepatitis B surface antigen (anti-HBs) be followed-up after discharge, if possible, and suggested that a short course of antiviral prophylaxis may be preferred. No hepatitis B surface antigen seroreversion was detected in their cohort and only two (3%) patients had detectable serum HBV-DNA.<xref rid="JCTH-D-21-00368-b30" ref-type="bibr">30</xref> In another study, liver injury was observed in COVID-19 patients with or without chronic HBV. Also, three patients experienced hepatitis B reactivation. Thus, monitoring of LFTs and HBV-DNA levels was recommended in COVID-19 patients treated with tocilizumab.<xref rid="JCTH-D-21-00368-b31" ref-type="bibr">31</xref></p><p>Furthermore, membrane transporters localized on the cell membrane, especially those on tissues in the central organ for drug metabolism, such as the liver, can effectively influence pharmacokinetic characteristics and ADEs. Canalicular ABC transporters in hepatocytes, such as ABCC2/MRP2, ABCG2/BCRP, ABCB1/MDR1/P-gp and ABCB11/BSEP, mediate the extrusion of endo- and xenobiotics into the bile. P-gp, MRP2 and ABCG2 are multispecific transporters mediating the efflux of hydrophobic or partially detoxified amphiphilic compounds. MRP2 is the key transporter for bilirubin conjugates. The SLC-type transporter MATE1 in the hepatocyte canalicular membrane mainly transports cationic drugs, but also some zwitterionic and anionic molecules,<xref rid="JCTH-D-21-00368-b68" ref-type="bibr">68</xref>,<xref rid="JCTH-D-21-00368-b69" ref-type="bibr">69</xref> and mediates their biliary excretion. Inhibition of these drug exporters may cause elevated liver toxicity, such as cholestasis or DILI. All of the above repurposed drugs have various effects in inducing DILI through the special inhibition to transporters. A recent study showed that lopinavir and ritonavir, given in low micromolar concentrations, inhibited BSEP and MATE1 exporters as well as OATP1B1/1B3 uptake transporters. Ritonavir had a similar inhibitory pattern but also inhibiting OCT1. Specifically, remdesivir strongly inhibited MRP4, OATP1B1/1B3, MATE1 and OCT1. Favipiravir had no significant effect on any of these transporters.<xref rid="JCTH-D-21-00368-b70" ref-type="bibr">70</xref></p><p>Corticosteroid is used in the treatment of a variety of inflammatory and autoimmune conditions. It is used at a wide range of doses, ranging from 0.5 to 80 mg daily.<xref rid="JCTH-D-21-00368-b71" ref-type="bibr">71</xref> Other glucocorticoids, including prednisolone, are used regularly for patients with significant liver disease in the treatment of autoimmune and alcoholic hepatitis, including for patients with cirrhosis, acute liver failure, ALT/AST &#x0003e;10&#x000d7;ULN and post-liver transplant.<xref rid="JCTH-D-21-00368-b72" ref-type="bibr">72</xref>,<xref rid="JCTH-D-21-00368-b73" ref-type="bibr">73</xref> Dexamethasone is metabolized in the liver via CYP3A4,<xref rid="JCTH-D-21-00368-b74" ref-type="bibr">74</xref> and has very limited influence in hepatic impairment, though its half-life is prolonged in severe liver disease.<xref rid="JCTH-D-21-00368-b71" ref-type="bibr">71</xref> Corticosteroid treatments are associated with hepatic steatosis, hepatic glycogenosis, and hepatic enlargement.<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref> Corticosteroids can also promote hepatic gluconeogenesis, reduce peripheral use of glucose, and increase insulin levels consequently. Glucocorticoids have a pro-adipogenic function of increasing deposition of abdominal fat, and leading to glucose intolerance and hypertriglyceridemia. In addition, these drugs play a role in controlling liver metabolism and can lead to the development of hepatic steatosis.<xref rid="JCTH-D-21-00368-b32" ref-type="bibr">32</xref> But, in COVID-19 patients, this effect is unlikely to be significant given the very low dose (6 mg daily) and short duration.<xref rid="JCTH-D-21-00368-b33" ref-type="bibr">33</xref> Although toxicities that may arise in long-term use are not a problem for COVID-19 patients, it should be considered that there are short-term risks, such as HBV reactivation.<xref rid="JCTH-D-21-00368-b30" ref-type="bibr">30</xref></p><p>Convalescent plasma has shown a potential therapeutic effect, with low risk for the treatment of severe COVID-19 patients.<xref rid="JCTH-D-21-00368-b34" ref-type="bibr">34</xref> At the same, there are still few experiences of convalescent plasma therapy in COVID-19 patients with chronic liver disease.<xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref></p><p>Azithromycin is a macrolide antibiotic used in treatment of various infections, such as community-acquired pneumonia, bronchitis, soft tissue infections and uncomplicated genital infections due to <italic>Chlamydia trachomatis</italic> and <italic>Neisseria gonorrhoeae</italic>. The liver is the main site for metabolism of azithromycin and 50% is excreted unchanged in the bile, although some inactive metabolites are also found.<xref rid="JCTH-D-21-00368-b35" ref-type="bibr">35</xref> A previous study demonstrated that azithromycin has an association with a low rate of acute, transient, and asymptomatic elevations in serum aminotransferases, occurring in 1% to 2% of patients treated for short periods.<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref> This drug can, thus, be exempted for further evaluation when used in COVID-19 patients, especially with low dose and short duration.</p><p>Ribavirin is a guanosine nucleoside analogue, approved for use in combination with direct acting antivirals or pegylated-interferon 2a or 2b for treatment of hepatitis C. In the treatment of hepatitis C, ribavirin is given orally and is dosed dependent on weight, ranging from 800 mg to 1200 mg daily. However, it has not been associated with serum aminotransferase elevations. Ribavirin treatment is usually used in COVID-19 patients with underlying liver disease; however, it is difficult to interpret increases in serum aminotransferase levels during therapy.<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref></p><p>Because of the fever and pain experienced by COVID-19 patients, several medicines agencies have warned physicians against the excessive use of non-steroidal anti-inflammatory drugs (NSAIDs), while the acetaminophen (paracetamol) was strongly recommended.<xref rid="JCTH-D-21-00368-b35" ref-type="bibr">35</xref> However, this recommendation could possibly result in the misuse of acetaminophen and consequently increase liver injury. Acetaminophen use is associated with generally mild ADEs, such as hepatitis, cholestasis, or other nonspecific liver enzyme elevation, but acetaminophen-induced hepatotoxicity is mostly estimated to account for 48% of acute liver injury diagnoses, providing caution for acetaminophen-caused dose-related hepatotoxicity.<xref rid="JCTH-D-21-00368-b36" ref-type="bibr">36</xref>,<xref rid="JCTH-D-21-00368-b37" ref-type="bibr">37</xref></p><p>Another important point is the potential drug-drug interactions (DDIs) between the drugs used in patients with transplantation (such as tacrolimus and steroids) and COVID-19. These DDIs may also indirectly increase the risk of hepatotoxicity if the effect of the immunosuppressive or the COVID-19 drug were to become altered pharmacodynamically or pharmacokinetically.<xref rid="JCTH-D-21-00368-b75" ref-type="bibr">75</xref></p></sec><sec id="s3b"><title>Clarify the liver injury by DILI vs. systemic inflammation from COVID-19</title><p>As described above, drugs implemented in the treatment may aggravate liver injury, which can occur besides the manifestation of COVID-19 or other underlying liver disease.<xref rid="JCTH-D-21-00368-b13" ref-type="bibr">13</xref> However, it was difficult to confirm the direct relationship between a specific drug and liver injury due to the combined use of all of above repurposed drugs during COVID-19.<xref rid="JCTH-D-21-00368-b14" ref-type="bibr">14</xref> According to the existing literature, we tried to conclude this complexity in order to caution the physicians and guide the drug use, and our findings are shown in <xref rid="JCTH-D-21-00368-t2" ref-type="table">Table 2</xref>.[10,16&#x02013;25,50&#x02013;52,27&#x02013;37,63&#x02013;67</p><table-wrap position="float" id="JCTH-D-21-00368-t2"><label>Table 2</label><caption><title>Potential ADEs of repurposed drugs on liver in COVID-19 patients and non-COVID-19 patients</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Drugs</th><th align="left" rowspan="1" colspan="1">COVID-19</th><th align="left" rowspan="1" colspan="1">Non-COVID-19</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">LPV/r</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+++</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref>,<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref>,<xref rid="JCTH-D-21-00368-b17" ref-type="bibr">17</xref>,<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b19" ref-type="bibr">19</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">_</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remdesivir</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b17" ref-type="bibr">17</xref>,<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b21" ref-type="bibr">21</xref>&#x02013;<xref rid="JCTH-D-21-00368-b25" ref-type="bibr">25</xref>,<xref rid="JCTH-D-21-00368-b50" ref-type="bibr">50</xref>,<xref rid="JCTH-D-21-00368-b51" ref-type="bibr">51</xref>,<xref rid="JCTH-D-21-00368-b52" ref-type="bibr">52</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+/&#x02212;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Favipiravir</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;/+</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b27" ref-type="bibr">27</xref>,<xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Umifenovir</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hydroxychloroquine</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;/+</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b20" ref-type="bibr">20</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Azithromycin</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;/+</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interferons</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+/&#x02212;</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Convalescent plasma (antibody)</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;/+</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref>,<xref rid="JCTH-D-21-00368-b34" ref-type="bibr">34</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Corticosteroids</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+/&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b30" ref-type="bibr">30</xref>,<xref rid="JCTH-D-21-00368-b32" ref-type="bibr">32</xref>,<xref rid="JCTH-D-21-00368-b33" ref-type="bibr">33</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tocilizumab</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+/&#x02212;</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b63" ref-type="bibr">63</xref>,<xref rid="JCTH-D-21-00368-b29" ref-type="bibr">29</xref>,<xref rid="JCTH-D-21-00368-b64" ref-type="bibr">64</xref>,<xref rid="JCTH-D-21-00368-b65" ref-type="bibr">65</xref>,<xref rid="JCTH-D-21-00368-b66" ref-type="bibr">66</xref>,<xref rid="JCTH-D-21-00368-b67" ref-type="bibr">67</xref>,<xref rid="JCTH-D-21-00368-b30" ref-type="bibr">30</xref>,<xref rid="JCTH-D-21-00368-b31" ref-type="bibr">31</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acetaminophen</td><td align="left" valign="top" rowspan="1" colspan="1">+</td><td align="left" valign="top" rowspan="1" colspan="1">+++</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b35" ref-type="bibr">35</xref>&#x02013;<xref rid="JCTH-D-21-00368-b37" ref-type="bibr">37</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">+/&#x02212;</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt102"><p>Note: In COVID-19 column: with COVID-19(+), without COVID-19(&#x02212;); in ADEs column: severe (+++), mild to Moderate (+), no ADEs (&#x02212;), possible ADEs (+/&#x02212;), possible no ADEs (&#x02212;/+), with no report (N/A). COVID-19, coronavirus disease 2019; ADEs, adverse drug events.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Recommendation on drug use in liver injury</title><p>Liver injury can change metabolism, excretion, dosing, and expected concentrations of drugs, which may make it difficult to achieve an effective therapeutic dose or can increase the risk of ADEs.<xref rid="JCTH-D-21-00368-b76" ref-type="bibr">76</xref></p><p>Acute liver injury has been commonly defined by the ULN of serum ALT, ALP, and serum concentration of total bilirubin based on the biological criteria, that is, elevation of ALT &#x02265;5&#x000d7;ULN or ALP &#x02265;2&#x000d7;ULN, or combination of ALT &#x02265;3&#x000d7;ULN with a simultaneous total bilirubin concentration exceeding 2 &#x000d7;ULN.<xref rid="JCTH-D-21-00368-b77" ref-type="bibr">77</xref>,<xref rid="JCTH-D-21-00368-b78" ref-type="bibr">78</xref></p><p>Till now, the pharmacokinetics of remdesivir have not been evaluated in patients with hepatic injury. Hence, the hepatic function should be monitored in all patients before initiating and during daily treatment with remdesivir. Currently, remdesivir is not recommended in patients with ALT &#x02265;5&#x000d7;ULN at baseline. It should be discontinued if ALT rises to higher than 5&#x000d7;ULN during treatment or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, ALP, or INR, however, this therapy can be restarted if ALT is less than 5&#x000d7;ULN<xref rid="JCTH-D-21-00368-b79" ref-type="bibr">79</xref>,<xref rid="JCTH-D-21-00368-b80" ref-type="bibr">80</xref></p><p>Since hydroxychloroquine commonly accumulates in the liver, it is recommended to monitor LFTs continuously and administrate it cautiously with concurrent hepatotoxic drugs.<xref rid="JCTH-D-21-00368-b81" ref-type="bibr">81</xref> It is also recommended that LFTs should be closely monitored for each patient while initiating tocilizumab; if ALT or AST are higher than 1.5&#x000d7;ULN, the treatment needs to be discontinued immediately.<xref rid="JCTH-D-21-00368-b82" ref-type="bibr">82</xref></p><p>Since LPV/r is primarily metabolized by the liver, it is recommended to evaluate patient response and use with caution in case of liver injury. Although there is no need to reduce the dose for mild to moderate hepatic injury, frequent monitoring of LFTs is strongly recommended.<xref rid="JCTH-D-21-00368-b33" ref-type="bibr">33</xref> LPV/r administration has not been studied in patients with severe hepatic injury and its use is contraindicated.<xref rid="JCTH-D-21-00368-b83" ref-type="bibr">83</xref></p><p>Azithromycin is eliminated predominantly in liver, and as such it should be used with caution due to its potential risk of hepatotoxicity and it should be avoided in patients with severe liver disease. A study has demonstrated that azithromycin pharmacokinetics do not differ consistently in patients with Child-Pugh A or B cirrhosis, in comparison with healthy volunteer; therefore, dosage modification is not required in these patient groups.<xref rid="JCTH-D-21-00368-b84" ref-type="bibr">84</xref> No difference in single-dose pharmacokinetics of ribavirin was noted in patients with mild, moderate, or severe hepatic dysfunction (Child-Pugh score A, B, or C).<xref rid="JCTH-D-21-00368-b85" ref-type="bibr">85</xref> Full-dose ribavirin can be used in severe hepatic dysfunction with caution; mild and moderate hepatic dysfunction associated renal impairment are suggested to make a proper dose reduction based on estimated glomerular filtration rate (eGFR).<xref rid="JCTH-D-21-00368-b33" ref-type="bibr">33</xref> Alteration of favipiravir dose is not recommended in mild and moderate hepatic impairment (Child-Pugh A and B), while it should be considered in severe hepatic injury (Child-Pugh C).<xref rid="JCTH-D-21-00368-b33" ref-type="bibr">33</xref></p><p>Altogether, the detailed information of these repurposed drugs for COVID-19 treatment, including the family of the drug, the mode of action, and the possible mechanism by which it induces liver injury, are presented in the <xref rid="JCTH-D-21-00368-t3" ref-type="table">Table 3</xref>.<xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref>,<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref>&#x02013;<xref rid="JCTH-D-21-00368-b25" ref-type="bibr">25</xref>,<xref rid="JCTH-D-21-00368-b50" ref-type="bibr">50</xref>&#x02013;<xref rid="JCTH-D-21-00368-b52" ref-type="bibr">52</xref>,<xref rid="JCTH-D-21-00368-b27" ref-type="bibr">27</xref>&#x02013;<xref rid="JCTH-D-21-00368-b37" ref-type="bibr">37</xref>,<xref rid="JCTH-D-21-00368-b63" ref-type="bibr">63</xref>&#x02013;<xref rid="JCTH-D-21-00368-b67" ref-type="bibr">67</xref></p><table-wrap position="float" id="JCTH-D-21-00368-t3"><label>Table 3</label><caption><title>Four categories of repurposed drugs for COVID-19 treatment and their detailed information</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Drug category</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="left" rowspan="1" colspan="1">Dose recommendation</th><th align="left" rowspan="1" colspan="1">Metabolism</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">I. Anti-malarial/anti-parasitic drugs</td><td align="left" valign="top" rowspan="1" colspan="1">Hydroxychloroquine</td><td align="left" valign="top" rowspan="1" colspan="1">Maximum dosage based on minimal data and risk of hepatotoxicity</td><td align="left" valign="top" rowspan="1" colspan="1">Major: CYP3A4/5, Minor: CYP2D6, CYP2C8</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b20" ref-type="bibr">20</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II. Drugs used for rheumatoid arthritis</td><td align="left" valign="top" rowspan="1" colspan="1">Hydroxychloroquine</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Tocilizumab</td><td align="left" valign="top" rowspan="1" colspan="1">In patients with baseline ALT or AST &#x0003e;5&#x000d7;ULN, treatment is not recommended</td><td align="left" valign="top" rowspan="1" colspan="1">Catabolic pathway</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b63" ref-type="bibr">63</xref>,<xref rid="JCTH-D-21-00368-b29" ref-type="bibr">29</xref>,<xref rid="JCTH-D-21-00368-b64" ref-type="bibr">64</xref>,<xref rid="JCTH-D-21-00368-b65" ref-type="bibr">65</xref>,<xref rid="JCTH-D-21-00368-b66" ref-type="bibr">66</xref>,<xref rid="JCTH-D-21-00368-b67" ref-type="bibr">67</xref>,<xref rid="JCTH-D-21-00368-b30" ref-type="bibr">30</xref>,<xref rid="JCTH-D-21-00368-b31" ref-type="bibr">31</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">corticosteroids</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1">Hydroxylation via CYP3A4, followed by glucuronidation or sulfation</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b30" ref-type="bibr">30</xref>,<xref rid="JCTH-D-21-00368-b32" ref-type="bibr">32</xref>,<xref rid="JCTH-D-21-00368-b33" ref-type="bibr">33</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Interferon-&#x003b2;</td><td align="left" valign="top" rowspan="1" colspan="1">Caution if ALT &#x0003e;2.5&#x000d7;ULN, Dose reduction advised if ALT &#x0003e;5&#x000d7;ULN</td><td align="left" valign="top" rowspan="1" colspan="1">Metabolized and excreted by liver and kidneys</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Azithromycin</td><td align="left" valign="top" rowspan="1" colspan="1">Discontinue if signs of hepatic dysfunction</td><td align="left" valign="top" rowspan="1" colspan="1">Liver: 35% to inactive metabolites</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III. Anti-retroviral/anti-viral drugs</td><td align="left" valign="top" rowspan="1" colspan="1">LPV/r</td><td align="left" valign="top" rowspan="1" colspan="1">Use with caution in mild to moderate hepatic impairment and monitor for toxicities</td><td align="left" valign="top" rowspan="1" colspan="1">CYP3A4/5, auto-induction own metabolism; stabilization after 10&#x02013;16 days</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b10" ref-type="bibr">10</xref>,<xref rid="JCTH-D-21-00368-b16" ref-type="bibr">16</xref>,<xref rid="JCTH-D-21-00368-b17" ref-type="bibr">17</xref>,<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b19" ref-type="bibr">19</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Remdesivir</td><td align="left" valign="top" rowspan="1" colspan="1">Discontinuation: ALT &#x0003e;5&#x000d7;ULN or ALT elevation</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>In vitro</italic>: CYP2C8 CYP2D6, CYP3A4, OATP1B1, P-gp substrate</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b17" ref-type="bibr">17</xref>,<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>,<xref rid="JCTH-D-21-00368-b21" ref-type="bibr">21</xref>&#x02013;<xref rid="JCTH-D-21-00368-b25" ref-type="bibr">25</xref>,<xref rid="JCTH-D-21-00368-b50" ref-type="bibr">50</xref>,<xref rid="JCTH-D-21-00368-b51" ref-type="bibr">51</xref>,<xref rid="JCTH-D-21-00368-b52" ref-type="bibr">52</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Favipiravir</td><td align="left" valign="top" rowspan="1" colspan="1">Dose adjustment should be considered</td><td align="left" valign="top" rowspan="1" colspan="1">Extensive metabolism by hydroxylation (aldehyde oxidase and xanthine oxidase) to M1 and M2</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b27" ref-type="bibr">27</xref>,<xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin</td><td align="left" valign="top" rowspan="1" colspan="1">Discontinue if progressive and clinically significant ALT rises, despite dose reduction, or accompanied by increased bilirubin</td><td align="left" valign="top" rowspan="1" colspan="1">Intracellular phosphorylation by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites</td><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="JCTH-D-21-00368-b18" ref-type="bibr">18</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IV. Others</td><td align="left" valign="top" rowspan="1" colspan="1">Acetaminophen</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b35" ref-type="bibr">35</xref>&#x02013;<xref rid="JCTH-D-21-00368-b37" ref-type="bibr">37</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Convalescent plasma (antibody)</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1">/</td><td align="left" valign="top" rowspan="1" colspan="1"><xref rid="JCTH-D-21-00368-b28" ref-type="bibr">28</xref>,<xref rid="JCTH-D-21-00368-b34" ref-type="bibr">34</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt103"><p>COVID-19, coronavirus disease 2019; ALT, alanine aminotransferase; AST, aspartate transaminase; LPV/r, lopinavir/ritonavir; ULN, upper limit of normal; CYP, cytochrome P450 enzymes; OATP, organic anion transporting polypeptide.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Conclusion</title><p>Through the last year, COVID-19 devastated our health care systems and invoked an unprecedented need for new treatment options to heal its notorious manifestations. The scientific community is still far from finding a &#x02018;silver bullet&#x02019; to overcome its detrimental effects; thus, some medications with limited <italic>in vitro</italic> activity against the eliciting virus are being repurposed for its treatment. Those repurposed drugs have had limited efficacy against the virus and the disease itself; however, they still pose risk of adverse effects. Close monitoring of liver functions in COVID-19 patients can provide early diagnosis of liver injury, and reduce the risk of DILI as much as possible. A special caution should be given to those patients who are liver-transplanted, for drug-drug interactions occurring under certain immunosuppressive therapies. Abnormal liver tests should not be a contraindication against use of COVID-19 experimental therapies, if needed.</p></sec><sec id="s5"><title>Limitations</title><p>Many measures have been applied against this virus during the pandemic, which have included officially approved Emergency Use Authorization (EUA) candidates and even some unofficial treatment methods. Among them, the repurposed old drugs have accounted for the majority in clinic, and most had been used before as anti-malarial/anti-parasitic, anti-retroviral/anti-viral, anti-cancer, or against rheumatoid arthritis drugs. Yet, there was no standard and systematic evaluation for their ADEs in COVID-19 patients, especially for their DILI aspects. As such, this review was limited by the ability to collect information on all of the repurposed drugs used worldwide. In-depth systematic exploration and discovery should be further improved for this topic.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge Professor Xigang Jing at the Medical College of Wisconsin, USA, for his expert opinions on pathology and virology in support of this review.</p></ack><ref-list><title>References</title><ref id="JCTH-D-21-00368-b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Nair</surname><given-names>N</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Sehrawat</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Extrapulmonary manifestations of COVID-19</article-title><source>Nature Med</source><year>2020</year><volume>26</volume><issue>7</issue><fpage>1017</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0968-3</pub-id><pub-id pub-id-type="pmid">32651579</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><name><surname>He</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>18</issue><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>FS</given-names></name></person-group><article-title>Liver injury in COVID-19: management and challenges</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><issue>5</issue><fpage>428</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(20)30057-1</pub-id><pub-id pub-id-type="pmid">32145190</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name></person-group><article-title>Liver injury during highly pathogenic human coronavirus infections</article-title><source>Liver Int</source><year>2020</year><volume>40</volume><issue>5</issue><fpage>998</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1111/liv.14435</pub-id><pub-id pub-id-type="pmid">32170806</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlotsky</surname><given-names>JM</given-names></name></person-group><article-title>COVID-19 and the liver-related deaths to come</article-title><source>Nature Rev Gastroenterol Hepatol</source><year>2020</year><volume>17</volume><issue>9</issue><fpage>523</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-0328-2</pub-id><pub-id pub-id-type="pmid">32528138</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olry</surname><given-names>A</given-names></name><name><surname>Meunier</surname><given-names>L</given-names></name><name><surname>D&#x000e9;lire</surname><given-names>B</given-names></name><name><surname>Larrey</surname><given-names>D</given-names></name><name><surname>Horsmans</surname><given-names>Y</given-names></name><name><surname>Le Lou&#x000eb;t</surname><given-names>H</given-names></name></person-group><article-title>Drug-induced liver injury and COVID-19 infection: The rules remain the same</article-title><source>Drug Saf</source><year>2020</year><volume>43</volume><issue>7</issue><fpage>615</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1007/s40264-020-00954-z</pub-id><pub-id pub-id-type="pmid">32514859</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>H</given-names></name><name><surname>Harmouch</surname><given-names>F</given-names></name><name><surname>Garg</surname><given-names>K</given-names></name><name><surname>Saraiya</surname><given-names>P</given-names></name><name><surname>Daly</surname><given-names>T</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><etal/></person-group><article-title>The liver in COVID-19: prevalence, patterns, predictors, and impact on outcomes of liver test abnormalities</article-title><source>Eur J Gastroenterol Hepatol</source><year>2020</year><pub-id pub-id-type="doi">10.1097/meg.0000000000002021</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boettler</surname><given-names>T</given-names></name><name><surname>Marjot</surname><given-names>T</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Mondelli</surname><given-names>MU</given-names></name><name><surname>Maticic</surname><given-names>M</given-names></name><name><surname>Cordero</surname><given-names>E</given-names></name><etal/></person-group><article-title>Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic</article-title><source>JHEP Rep</source><year>2020</year><volume>2</volume><issue>5</issue><fpage>100169</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2020.100169</pub-id><pub-id pub-id-type="pmid">32835190</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name></person-group><article-title>Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China</article-title><source>Liver Int</source><year>2020</year><volume>40</volume><issue>9</issue><fpage>2095</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1111/liv.14455</pub-id><pub-id pub-id-type="pmid">32239796</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group><article-title>COVID-19: Abnormal liver function tests</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><issue>3</issue><fpage>566</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.04.006</pub-id><pub-id pub-id-type="pmid">32298767</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Ou</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><etal/></person-group><article-title>COVID-19 in a designated infectious diseases hospital outside Hubei Province, China</article-title><source>Allergy</source><year>2020</year><volume>75</volume><issue>7</issue><fpage>1742</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.1111/all.14309</pub-id><pub-id pub-id-type="pmid">32239761</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Clinical features of patients with COVID-19 with nonalcoholic fatty liver disease</article-title><source>Hepatol Commun</source><year>2020</year><volume>4</volume><issue>12</issue><fpage>1758</fpage><lpage>1768</lpage><pub-id pub-id-type="doi">10.1002/hep4.1592</pub-id><pub-id pub-id-type="pmid">32838108</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alqahtani</surname><given-names>SA</given-names></name><name><surname>Schattenberg</surname><given-names>JM</given-names></name></person-group><article-title>Liver injury in COVID-19: The current evidence</article-title><source>United European Gastroenterol J</source><year>2020</year><volume>8</volume><issue>5</issue><fpage>509</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1177/2050640620924157</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brito</surname><given-names>CA</given-names></name><name><surname>Barros</surname><given-names>FM</given-names></name><name><surname>Lopes</surname><given-names>EP</given-names></name></person-group><article-title>Mechanisms and consequences of COVID-19 associated liver injury: What can we affirm?</article-title><source>World J Hepatol</source><year>2020</year><volume>12</volume><issue>8</issue><fpage>413</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.4254/wjh.v12.i8.413</pub-id><pub-id pub-id-type="pmid">32952870</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>JM</given-names></name><name><surname>Monogue</surname><given-names>ML</given-names></name><name><surname>Jodlowski</surname><given-names>TZ</given-names></name><name><surname>Cutrell</surname><given-names>JB</given-names></name></person-group><article-title>Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>18</issue><fpage>1824</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.6019</pub-id><pub-id pub-id-type="pmid">32282022</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Incidence of adverse drug reactions in COVID-19 patients in China: An active monitoring study by hospital pharmacovigilance system</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>108</volume><issue>4</issue><fpage>791</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1002/cpt.1866</pub-id><pub-id pub-id-type="pmid">32324898</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>AV</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Tevethia</surname><given-names>HV</given-names></name><name><surname>Premkumar</surname><given-names>M</given-names></name><name><surname>Arab</surname><given-names>JP</given-names></name><name><surname>Candia</surname><given-names>R</given-names></name><etal/></person-group><article-title>Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19</article-title><source>Aliment Pharmacol Ther</source><year>2020</year><volume>52</volume><issue>4</issue><fpage>584</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1111/apt.15916</pub-id><pub-id pub-id-type="pmid">32638436</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Her</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name></person-group><article-title>Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis</article-title><source>Rheumatol Int</source><year>2011</year><volume>31</volume><issue>1</issue><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1007/s00296-009-1237-4</pub-id><pub-id pub-id-type="pmid">19885660</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical features of COVID-19-related liver functional abnormality</article-title><source>Clin Gastroenterol Hepatol</source><year>2020</year><volume>18</volume><issue>7</issue><fpage>1561</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2020.04.002</pub-id><pub-id pub-id-type="pmid">32283325</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falc&#x000e3;o</surname><given-names>MB</given-names></name><name><surname>Pamplona de G&#x000f3;es Cavalcanti</surname><given-names>L</given-names></name><name><surname>Filgueiras Filho</surname><given-names>NM</given-names></name><name><surname>Antunes de Brito</surname><given-names>CA</given-names></name></person-group><article-title>Case report: Hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19</article-title><source>Am J Trop Med Hyg</source><year>2020</year><volume>102</volume><issue>6</issue><fpage>1214</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.20-0276</pub-id><pub-id pub-id-type="pmid">32314698</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Tomashek</surname><given-names>KM</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Zingman</surname><given-names>BS</given-names></name><name><surname>Kalil</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Remdesivir for the treatment of Covid-19-Final report</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>19</issue><fpage>1813</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id><pub-id pub-id-type="pmid">32445440</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>JD</given-names></name><name><surname>Lye</surname><given-names>DCB</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Marks</surname><given-names>KM</given-names></name><name><surname>Bruno</surname><given-names>R</given-names></name><name><surname>Montejano</surname><given-names>R</given-names></name><etal/></person-group><article-title>Remdesivir for 5 or 10 days in patients with severe Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>19</issue><fpage>1827</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2015301</pub-id><pub-id pub-id-type="pmid">32459919</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinner</surname><given-names>CD</given-names></name><name><surname>Gottlieb</surname><given-names>RL</given-names></name><name><surname>Criner</surname><given-names>GJ</given-names></name><name><surname>Arribas L&#x000f3;pez</surname><given-names>JR</given-names></name><name><surname>Cattelan</surname><given-names>AM</given-names></name><name><surname>Soriano Viladomiu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of Remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial</article-title><source>JAMA</source><year>2020</year><volume>324</volume><issue>11</issue><fpage>1048</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.16349</pub-id><pub-id pub-id-type="pmid">32821939</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>J</given-names></name><name><surname>Ohmagari</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Diaz</surname><given-names>G</given-names></name><name><surname>Asperges</surname><given-names>E</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><etal/></person-group><article-title>Compassionate use of Remdesivir for patients with severe Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>24</issue><fpage>2327</fpage><lpage>2336</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2007016</pub-id><pub-id pub-id-type="pmid">32275812</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Du</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10236</issue><fpage>1569</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id><pub-id pub-id-type="pmid">32423584</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b26"><label>26</label><element-citation publication-type="webpage"><comment>Fujifilm Pharmaceuticals U.S.A., Inc. Study of the use of Favipiravir in hospitalized subjects with COVID-19. 2020. Available from: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04358549" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04358549</ext-link></comment></element-citation></ref><ref id="JCTH-D-21-00368-b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>D</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><etal/></person-group><article-title>Experimental treatment with Favipiravir for COVID-19: An open-label control study</article-title><source>Engineering (Beijing)</source><year>2020</year><volume>6</volume><issue>10</issue><fpage>1192</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1016/j.eng.2020.03.007</pub-id><pub-id pub-id-type="pmid">32346491</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boettler</surname><given-names>T</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Mondelli</surname><given-names>MU</given-names></name><name><surname>Maticic</surname><given-names>M</given-names></name><name><surname>Cordero</surname><given-names>E</given-names></name><name><surname>Cornberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper</article-title><source>JHEP Rep</source><year>2020</year><volume>2</volume><issue>3</issue><fpage>100113</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2020.100113</pub-id><pub-id pub-id-type="pmid">32289115</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michot</surname><given-names>JM</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Saada</surname><given-names>V</given-names></name><name><surname>Pommeret</surname><given-names>F</given-names></name><name><surname>Griscelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report</article-title><source>Ann Oncol</source><year>2020</year><volume>31</volume><issue>7</issue><fpage>961</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.03.300</pub-id><pub-id pub-id-type="pmid">32247642</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Tajes</surname><given-names>S</given-names></name><name><surname>Miralpeix</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>J</given-names></name><name><surname>L&#x000f3;pez-Su&#x000f1;&#x000e9;</surname><given-names>E</given-names></name><name><surname>Laguno</surname><given-names>M</given-names></name><name><surname>Pocurull</surname><given-names>A</given-names></name><etal/></person-group><article-title>Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy</article-title><source>J Viral Hepat</source><year>2021</year><volume>28</volume><issue>1</issue><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/jvh.13410</pub-id><pub-id pub-id-type="pmid">32969557</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><etal/></person-group><article-title>Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection</article-title><source>Hepatol Res</source><year>2020</year><volume>50</volume><issue>11</issue><fpage>1211</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1111/hepr.13553</pub-id><pub-id pub-id-type="pmid">32761993</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessi</surname><given-names>J</given-names></name><name><surname>de Oliveira</surname><given-names>GB</given-names></name><name><surname>Schaan</surname><given-names>BD</given-names></name><name><surname>Telo</surname><given-names>GH</given-names></name></person-group><article-title>Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes</article-title><source>Diabetol Metab Syndr</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>80</fpage><pub-id pub-id-type="doi">10.1186/s13098-020-00583-7</pub-id><pub-id pub-id-type="pmid">32922517</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname><given-names>F</given-names></name><name><surname>Smolders</surname><given-names>EJ</given-names></name><name><surname>El-Sherif</surname><given-names>O</given-names></name><name><surname>Boyle</surname><given-names>A</given-names></name><name><surname>Davidson</surname><given-names>K</given-names></name><name><surname>Sommerville</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment</article-title><source>Drugs R D</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>9</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s40268-020-00333-0</pub-id><pub-id pub-id-type="pmid">33336316</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>17</issue><fpage>9490</fpage><lpage>9496</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id><pub-id pub-id-type="pmid">32253318</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>N</given-names></name><name><surname>Bosco-Levy</surname><given-names>P</given-names></name><name><surname>Thurin</surname><given-names>N</given-names></name><name><surname>Blin</surname><given-names>P</given-names></name><name><surname>Droz-Perroteau</surname><given-names>C</given-names></name></person-group><article-title>NSAIDs and COVID-19: A systematic review and meta-analysis</article-title><source>Drug Saf</source><year>2021</year><volume>44</volume><fpage>929</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1007/s40264-021-01089-5</pub-id><pub-id pub-id-type="pmid">34339037</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>E</given-names></name><name><surname>Babar</surname><given-names>A</given-names></name><name><surname>Choudhary</surname><given-names>M</given-names></name><name><surname>Kutner</surname><given-names>M</given-names></name><name><surname>Pyrsopoulos</surname><given-names>N</given-names></name></person-group><article-title>Acetaminophen-induced hepatotoxicity: a comprehensive update</article-title><source>J Clin Transl Hepatol</source><year>2016</year><volume>4</volume><issue>2</issue><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.14218/jcth.2015.00052</pub-id><pub-id pub-id-type="pmid">27350943</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunchorntavakul</surname><given-names>C</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name></person-group><article-title>Acetaminophen-related hepatotoxicity</article-title><source>Clin Liver Dis</source><year>2013</year><volume>17</volume><issue>4</issue><fpage>587</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2013.07.005</pub-id><pub-id pub-id-type="pmid">24099020</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b38"><label>38</label><element-citation publication-type="journal"><article-title>Truven Health Analytics Inc. and Micromedex Inc., Micromedex gateway 2011, Truven Health Analytics</article-title></element-citation></ref><ref id="JCTH-D-21-00368-b39"><label>39</label><element-citation publication-type="journal"><article-title>Plaquenil Hydroxychloroquine Sulfate Tablets US Prescribing Information 2017</article-title></element-citation></ref><ref id="JCTH-D-21-00368-b40"><label>40</label><element-citation publication-type="journal"><article-title>Plaquenil-Hydroxychloroquine sulfate 200mg Film-coated Tablets, Summary of Product Characteristics. Zentiva; 2020</article-title></element-citation></ref><ref id="JCTH-D-21-00368-b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dollery</surname><given-names>C</given-names></name></person-group><article-title>Therapeutic drugs. 2nd ed. Churchill Livingstone, London; 1998</article-title></element-citation></ref><ref id="JCTH-D-21-00368-b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McChesney</surname><given-names>EW</given-names></name></person-group><article-title>Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate</article-title><source>Am J Med</source><year>1983</year><volume>75</volume><issue>1A</issue><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(83)91265-2</pub-id><pub-id pub-id-type="pmid">6408923</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tett</surname><given-names>SE</given-names></name><name><surname>Cutler</surname><given-names>DJ</given-names></name><name><surname>Day</surname><given-names>RO</given-names></name><name><surname>Brown</surname><given-names>KF</given-names></name></person-group><article-title>Bioavailability of hydroxychloroquine tablets in healthy volunteers</article-title><source>Br J Clin Pharmacol</source><year>1989</year><volume>27</volume><issue>6</issue><fpage>771</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1989.tb03439.x</pub-id><pub-id pub-id-type="pmid">2757893</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warhurst</surname><given-names>DC</given-names></name><name><surname>Steele</surname><given-names>JC</given-names></name><name><surname>Adagu</surname><given-names>IS</given-names></name><name><surname>Craig</surname><given-names>JC</given-names></name><name><surname>Cullander</surname><given-names>C</given-names></name></person-group><article-title>Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant plasmodium falciparum, in agreement with its physicochemical properties</article-title><source>J Antimicrob Chemother</source><year>2003</year><volume>52</volume><issue>2</issue><fpage>188</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg319</pub-id><pub-id pub-id-type="pmid">12837731</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>A</given-names></name><name><surname>Saunders</surname><given-names>OL</given-names></name><name><surname>Butler</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Vela</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Synthesis and antiviral activity of a series of 1&#x02032;-substituted 4-aza-7,9-dideazaadenosine C-nucleosides</article-title><source>Bioorg Med Chem Lett</source><year>2012</year><volume>22</volume><issue>8</issue><fpage>2705</fpage><lpage>2707</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.02.105</pub-id><pub-id pub-id-type="pmid">22446091</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Hui</surname><given-names>HC</given-names></name><name><surname>Doerffler</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>MO</given-names></name><name><surname>Chun</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1- ftriazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses</article-title><source>J Med Chem</source><year>2017</year><volume>60</volume><issue>5</issue><fpage>1648</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01594</pub-id><pub-id pub-id-type="pmid">28124907</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Case</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</article-title><source>Sci Transl Med</source><year>2017</year><volume>9</volume><issue>396</issue><fpage>eaal3653</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aal3653</pub-id><pub-id pub-id-type="pmid">28659436</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Cronin</surname><given-names>J</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>12</issue><fpage>6771</fpage><lpage>6776</lpage><pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id><pub-id pub-id-type="pmid">32054787</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><issue>3</issue><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabers</surname><given-names>AJ</given-names></name><name><surname>Williams</surname><given-names>AL</given-names></name><name><surname>Farley</surname><given-names>TM</given-names></name></person-group><article-title>Use of Remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection</article-title><source>BMJ Case Rep</source><year>2020</year><volume>13</volume><issue>10</issue><fpage>e239210</fpage><pub-id pub-id-type="doi">10.1136/bcr-2020-239210</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leegwater</surname><given-names>E</given-names></name><name><surname>Strik</surname><given-names>A</given-names></name><name><surname>Wilms</surname><given-names>EB</given-names></name><name><surname>Bosma</surname><given-names>LBE</given-names></name><name><surname>Burger</surname><given-names>DM</given-names></name><name><surname>Ottens</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Drug-induced liver injury in a patient with coronavirus disease 2019: Potential interaction of Remdesivir with p-Glycoprotein inhibitors</article-title><source>Clin Infect Dis</source><year>2021</year><volume>72</volume><issue>7</issue><fpage>1256</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa883</pub-id><pub-id pub-id-type="pmid">32594120</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carothers</surname><given-names>C</given-names></name><name><surname>Birrer</surname><given-names>K</given-names></name><name><surname>Vo</surname><given-names>M</given-names></name></person-group><article-title>Acetylcysteine for the treatment of suspected Remdesivir-associated acute liver failure in COVID-19: A case series</article-title><source>Pharmacotherapy</source><year>2020</year><volume>40</volume><issue>11</issue><fpage>1166</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1002/phar.2464</pub-id><pub-id pub-id-type="pmid">33006138</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranovich</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Marjuki</surname><given-names>H</given-names></name><name><surname>Webby</surname><given-names>RJ</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><etal/></person-group><article-title>T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro</article-title><source>J Virol</source><year>2013</year><volume>87</volume><issue>7</issue><fpage>3741</fpage><lpage>3751</lpage><pub-id pub-id-type="doi">10.1128/JVI.02346-12</pub-id><pub-id pub-id-type="pmid">23325689</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Kuno-Maekawa</surname><given-names>M</given-names></name><name><surname>Sangawa</surname><given-names>H</given-names></name><name><surname>Uehara</surname><given-names>S</given-names></name><name><surname>Kozaki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mechanism of action of T-705 against influenza virus</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><issue>3</issue><fpage>981</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.3.981-986.2005</pub-id><pub-id pub-id-type="pmid">15728892</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Smith</surname><given-names>LK</given-names></name><name><surname>Rajwanshi</surname><given-names>VK</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Deval</surname><given-names>J</given-names></name></person-group><article-title>The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5&#x02032;-triphosphate towards influenza A virus polymerase</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>7</issue><fpage>e68347</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0068347</pub-id><pub-id pub-id-type="pmid">23874596</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smee</surname><given-names>DF</given-names></name><name><surname>Hurst</surname><given-names>BL</given-names></name><name><surname>Egawa</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Kadota</surname><given-names>T</given-names></name><name><surname>Furuta</surname><given-names>Y</given-names></name></person-group><article-title>Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells</article-title><source>J Antimicrob Chemother</source><year>2009</year><volume>64</volume><issue>4</issue><fpage>741</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1093/jac/dkp274</pub-id><pub-id pub-id-type="pmid">19643775</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderlinden</surname><given-names>E</given-names></name><name><surname>Vrancken</surname><given-names>B</given-names></name><name><surname>Van Houdt</surname><given-names>J</given-names></name><name><surname>Rajwanshi</surname><given-names>VK</given-names></name><name><surname>Gillemot</surname><given-names>S</given-names></name><name><surname>Andrei</surname><given-names>G</given-names></name><etal/></person-group><article-title>Distinct effects of T-705 (Favipiravir) and Ribavirin on influenza virus replication and viral RNA synthesis</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>11</issue><fpage>6679</fpage><lpage>6691</lpage><pub-id pub-id-type="doi">10.1128/AAC.01156-16</pub-id><pub-id pub-id-type="pmid">27572398</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Komeno</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title><source>Proc Jpn Acad Ser B Phys Biol Sci</source><year>2017</year><volume>93</volume><issue>7</issue><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.2183/pjab.93.027</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowen</surname><given-names>BB</given-names></name><name><surname>Wong</surname><given-names>MH</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Sanders</surname><given-names>AB</given-names></name><name><surname>Mendenhall</surname><given-names>M</given-names></name><name><surname>Bailey</surname><given-names>KW</given-names></name><etal/></person-group><article-title>In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><issue>9</issue><fpage>3168</fpage><lpage>3176</lpage><pub-id pub-id-type="doi">10.1128/AAC.00356-07</pub-id><pub-id pub-id-type="pmid">17606691</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safronetz</surname><given-names>D</given-names></name><name><surname>Rosenke</surname><given-names>K</given-names></name><name><surname>Westover</surname><given-names>JB</given-names></name><name><surname>Martellaro</surname><given-names>C</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Furuta</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>14775</fpage><pub-id pub-id-type="doi">10.1038/srep14775</pub-id><pub-id pub-id-type="pmid">26456301</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha-Pereira</surname><given-names>J</given-names></name><name><surname>Jochmans</surname><given-names>D</given-names></name><name><surname>Dallmeier</surname><given-names>K</given-names></name><name><surname>Leyssen</surname><given-names>P</given-names></name><name><surname>Nascimento</surname><given-names>MS</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name></person-group><article-title>Favipiravir (T-705) inhibits in vitro norovirus replication</article-title><source>Biochem Biophys Res Commun</source><year>2012</year><volume>424</volume><issue>4</issue><fpage>777</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.07.034</pub-id><pub-id pub-id-type="pmid">22809499</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidwell</surname><given-names>RW</given-names></name><name><surname>Barnard</surname><given-names>DL</given-names></name><name><surname>Day</surname><given-names>CW</given-names></name><name><surname>Smee</surname><given-names>DF</given-names></name><name><surname>Bailey</surname><given-names>KW</given-names></name><name><surname>Wong</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><issue>3</issue><fpage>845</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1128/AAC.01051-06</pub-id><pub-id pub-id-type="pmid">17194832</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Tattersall</surname><given-names>RS</given-names></name><name><surname>Manson</surname><given-names>JJ</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Tocilizumab treatment in COVID-19: A single center experience</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>7</issue><fpage>814</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1002/jmv.25801</pub-id><pub-id pub-id-type="pmid">32253759</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Frigault</surname><given-names>MJ</given-names></name><name><surname>Serling-Boyd</surname><given-names>NJ</given-names></name><name><surname>Fernandes</surname><given-names>AD</given-names></name><name><surname>Harvey</surname><given-names>L</given-names></name><name><surname>Foulkes</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Efficacy of Tocilizumab in patients hospitalized with Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><issue>24</issue><fpage>2333</fpage><lpage>2344</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2028836</pub-id><pub-id pub-id-type="pmid">33085857</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhovi&#x00107;</surname><given-names>D</given-names></name><name><surname>Bojovi&#x00107;</surname><given-names>J</given-names></name><name><surname>Bulatovi&#x00107;</surname><given-names>A</given-names></name><name><surname>Vuk&#x0010d;evi&#x00107;</surname><given-names>B</given-names></name><name><surname>Ratkovi&#x00107;</surname><given-names>M</given-names></name><name><surname>Lazovi&#x00107;</surname><given-names>R</given-names></name><etal/></person-group><article-title>First case of drug-induced liver injury associated with the use of Tocilizumab in a patient with COVID-19</article-title><source>Liver Int</source><year>2020</year><volume>40</volume><issue>8</issue><fpage>1901</fpage><lpage>1905</lpage><pub-id pub-id-type="doi">10.1111/liv.14516</pub-id><pub-id pub-id-type="pmid">32478465</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LF</given-names></name><name><surname>Mo</surname><given-names>YQ</given-names></name><name><surname>Jing</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>JD</given-names></name><name><surname>Zheng</surname><given-names>DH</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name></person-group><article-title>Short-course Tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation</article-title><source>Int J Rheum Dis</source><year>2017</year><volume>20</volume><issue>7</issue><fpage>859</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.13010</pub-id><pub-id pub-id-type="pmid">28160426</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koepsell</surname><given-names>H</given-names></name></person-group><article-title>Organic cation transporters in health and disease</article-title><source>Pharmacol Rev</source><year>2020</year><volume>72</volume><issue>1</issue><fpage>253</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1124/pr.118.015578</pub-id><pub-id pub-id-type="pmid">31852803</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonezawa</surname><given-names>A</given-names></name><name><surname>Inui</surname><given-names>K</given-names></name></person-group><article-title>Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics</article-title><source>Br J Pharmacol</source><year>2011</year><volume>164</volume><fpage>1817</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01394.x</pub-id><pub-id pub-id-type="pmid">21457222</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrus</surname><given-names>C</given-names></name><name><surname>Bakos</surname><given-names>&#x000c9;</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name><name><surname>&#x000d6;zvegy-Laczka</surname><given-names>C</given-names></name><name><surname>Telbisz</surname><given-names>&#x000c1;</given-names></name></person-group><article-title>Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>17810</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-97160-3</pub-id><pub-id pub-id-type="pmid">34497279</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b71"><label>71</label><element-citation publication-type="webpage"><comment>Aspen. Dexamethasone 2mg tablets, Summary of Product Characteristics; Accessed 10 Nov 2020. Available from: <ext-link xlink:href="https://www.medicines.org.uk/emc/product/5411/smpc" ext-link-type="uri">https://www.medicines.org.uk/emc/product/5411/smpc</ext-link></comment></element-citation></ref><ref id="JCTH-D-21-00368-b72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>HY</given-names></name><name><surname>Xie</surname><given-names>GJ</given-names></name><name><surname>Liu</surname><given-names>HM</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Evaluation of the efficacy of steroid therapy on acute liver failure</article-title><source>Exp Ther Med</source><year>2016</year><volume>12</volume><issue>5</issue><fpage>3121</fpage><lpage>3129</lpage><pub-id pub-id-type="doi">10.3892/etm.2016.3720</pub-id><pub-id pub-id-type="pmid">27882127</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneghan</surname><given-names>MA</given-names></name><name><surname>Yeoman</surname><given-names>AD</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Longhi</surname><given-names>MS</given-names></name></person-group><article-title>Autoimmune hepatitis</article-title><source>Lancet</source><year>2013</year><volume>382</volume><issue>9902</issue><fpage>1433</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)62163-1</pub-id><pub-id pub-id-type="pmid">23768844</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>ES</given-names></name><name><surname>Maggs</surname><given-names>JL</given-names></name><name><surname>Park</surname><given-names>BK</given-names></name><name><surname>Back</surname><given-names>DJ</given-names></name></person-group><article-title>Dexamethasone metabolism in vitro: species differences</article-title><source>J Steroid Biochem Mol Biol</source><year>1997</year><volume>62</volume><issue>4</issue><fpage>345</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/s0960-0760(97)00038-1</pub-id><pub-id pub-id-type="pmid">9408089</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Kassas</surname><given-names>M</given-names></name><name><surname>Alboraie</surname><given-names>M</given-names></name><name><surname>Al Balakosy</surname><given-names>A</given-names></name><name><surname>Abdeen</surname><given-names>N</given-names></name><name><surname>Afify</surname><given-names>S</given-names></name><name><surname>Abdalgaber</surname><given-names>M</given-names></name><etal/></person-group><article-title>Liver transplantation in the era of COVID-19</article-title><source>Arab J Gastroenterol</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.ajg.2020.04.019</pub-id><pub-id pub-id-type="pmid">32439237</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rismanbaf</surname><given-names>A</given-names></name><name><surname>Zarei</surname><given-names>S</given-names></name></person-group><article-title>Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor</article-title><source>Arch Acad Emerg Med</source><year>2020</year><volume>8</volume><issue>1</issue><fpage>e17</fpage><pub-id pub-id-type="pmid">32185369</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>RJ</given-names></name><name><surname>Seeff</surname><given-names>LB</given-names></name><name><surname>Andrade</surname><given-names>RJ</given-names></name><name><surname>Bj&#x000f6;rnsson</surname><given-names>ES</given-names></name><name><surname>Day</surname><given-names>CP</given-names></name><name><surname>Serrano</surname><given-names>J</given-names></name><etal/></person-group><article-title>Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop</article-title><source>Hepatol</source><year>2010</year><volume>52</volume><issue>2</issue><fpage>730</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1002/hep.23696</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>RJ</given-names></name><name><surname>Aithal</surname><given-names>GP</given-names></name><name><surname>Bj&#x000f6;rnsson</surname><given-names>ES</given-names></name><name><surname>Kaplowitz</surname><given-names>N</given-names></name><name><surname>Kullak-Ublick</surname><given-names>GA</given-names></name><name><surname>Larrey</surname><given-names>D</given-names></name><etal/></person-group><article-title>EASL clinical practice guidelines: drug-induced liver injury</article-title><source>J Hepatol</source><year>2019</year><volume>70</volume><issue>6</issue><fpage>1222</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.02.014</pub-id><pub-id pub-id-type="pmid">30926241</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malin</surname><given-names>JJ</given-names></name><name><surname>Su&#x000e1;rez</surname><given-names>I</given-names></name><name><surname>Priesner</surname><given-names>V</given-names></name><name><surname>F&#x000e4;tkenheuer</surname><given-names>G</given-names></name><name><surname>Rybniker</surname><given-names>J</given-names></name></person-group><article-title>Remdesivir against COVID-19 and other viral diseases</article-title><source>Clin Microbiol Rev</source><year>2020</year><volume>34</volume><issue>1</issue><fpage>e00162</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1128/CMR.00162-20</pub-id><pub-id pub-id-type="pmid">33055231</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>YN</given-names></name></person-group><article-title>Remdesivir: first approval</article-title><source>Drugs</source><year>2020</year><volume>80</volume><issue>13</issue><fpage>1355</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01378-w</pub-id><pub-id pub-id-type="pmid">32870481</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piszczatoski</surname><given-names>CR</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name></person-group><article-title>Emergency authorization of chloroquine and hydroxychloroquine for treatment of COVID-19</article-title><source>Ann Pharmacother</source><year>2020</year><volume>54</volume><issue>8</issue><fpage>827</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1177/1060028020925558</pub-id><pub-id pub-id-type="pmid">32389025</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies</article-title><source>Eur J Clin Pharmacol</source><year>2021</year><volume>77</volume><issue>3</issue><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1007/s00228-020-03017-5</pub-id><pub-id pub-id-type="pmid">33051695</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stower</surname><given-names>H</given-names></name></person-group><article-title>Lopinavir-ritonavir in severe COVID-19</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>4</issue><fpage>465</fpage><pub-id pub-id-type="doi">10.1038/s41591-020-0849-9</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzei</surname><given-names>T</given-names></name><name><surname>Surrenti</surname><given-names>C</given-names></name><name><surname>Novelli</surname><given-names>A</given-names></name><name><surname>Crispo</surname><given-names>A</given-names></name><name><surname>Fallani</surname><given-names>S</given-names></name><name><surname>Carl&#x000e0;</surname><given-names>V</given-names></name><etal/></person-group><article-title>Pharmacokinetics of azithromycin in patients with impaired hepatic function</article-title><source>J Antimicrob Chemother</source><year>1993</year><volume>31</volume><issue>Suppl E</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1093/jac/31.suppl_e.57</pub-id></element-citation></ref><ref id="JCTH-D-21-00368-b85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falade-Nwulia</surname><given-names>O</given-names></name><name><surname>Suarez-Cuervo</surname><given-names>C</given-names></name><name><surname>Nelson</surname><given-names>DR</given-names></name><name><surname>Fried</surname><given-names>MW</given-names></name><name><surname>Segal</surname><given-names>JB</given-names></name><name><surname>Sulkowski</surname><given-names>MS</given-names></name></person-group><article-title>Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review</article-title><source>Ann Intern Med</source><year>2017</year><volume>166</volume><issue>9</issue><fpage>637</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.7326/M16-2575</pub-id><pub-id pub-id-type="pmid">28319996</pub-id></element-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>ADEs</term><def><p>adverse drug events</p></def></def-item><def-item><term>ALP</term><def><p>alkaline phosphatase</p></def></def-item><def-item><term>ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p>aspartate transaminase</p></def></def-item><def-item><term>COVID-19</term><def><p>coronavirus disease 2019</p></def></def-item><def-item><term>CPT</term><def><p>Child Pugh Turcotte</p></def></def-item><def-item><term>CYP</term><def><p>cytochrome P450 enzymes</p></def></def-item><def-item><term>DILI</term><def><p>drug-induced liver injury</p></def></def-item><def-item><term>GGT</term><def><p>gamma-glutamyl transferase</p></def></def-item><def-item><term>LFT</term><def><p>liver function test</p></def></def-item><def-item><term>LPV/r</term><def><p>lopinavir/ritonavir</p></def></def-item><def-item><term>OATP</term><def><p>organic anion transporting polypeptide</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p>severe acute respiratory syndrome-coronavirus-2</p></def></def-item><def-item><term>ULN</term><def><p>upper limit of normal</p></def></def-item></def-list></glossary></back></article>
